ChrysCapital-backed Intas Pharma weighs $1-bn bid for Biogen's biosimilars biz

Premium

Intas Pharmaceuticals Ltd is preparing a bid for Biogen Inc.’s biosimilar business in a transaction that could be valued at as much as $1 billion, two people familiar with the talks said. Ahmedabad-based Intas is being advised by Goldman Sachs Group Inc., one of the people said, adding that the company ......